Milestone Pharmaceuticals (MIST) vs RenovoRx (RNXT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
RenovoRx (RNXT) has outperformed Milestone Pharmaceuticals (MIST) over the past year, gaining 18.3% versus a loss of 84.5%. Over five years, RNXT leads with a -85.3% price change compared with -93.8% for MIST. Milestone Pharmaceuticals is the larger company by market cap ($46.2 million vs $45.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MIST | RNXT |
|---|---|---|
| Share price | $0.3711 | $0.942 |
| Market cap | $46.20M | $45.45M |
| 1-day change | -7.06% | -10.29% |
| YTD return | -81.63% | +12.14% |
| 1-year return | -84.54% | +18.34% |
| 5-year return | -93.85% | -85.26% |
| EPS (TTM) | $-0.74 | $-0.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.12M |
| Revenue growth (YoY) | — | +2511.63% |
| Net income (latest FY) | $-63.06M | $-11.17M |
| Gross margin | — | 70.88% |
| Operating margin | — | -1113.98% |
| Net margin | — | -994.48% |
| 52-week high | $3.06 | $2.59 |
| 52-week low | $0.362 | $0.77 |
| Distance from 52-week high | -87.87% | -63.63% |
| Analyst consensus | none | none |
| Avg. price target upside | +1479.09% | +656.90% |
| Average volume | 1.53M | 815.75K |
| Shares outstanding | 124.50M | 48.25M |
| Employees | 38 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RNXT has outperformed MIST by 102.9 percentage points over the past year.
About Milestone Pharmaceuticals
MIST stock →Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees
About RenovoRx
RNXT stock →RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
MIST vs RNXT FAQ
Which is bigger, Milestone Pharmaceuticals or RenovoRx?
Milestone Pharmaceuticals (MIST) is larger, with a market capitalization of $46.20M compared with $45.45M for RenovoRx (RNXT).
Which stock has performed better over the past year, MIST or RNXT?
RNXT returned +18.34% over the past 12 months, compared with -84.54% for MIST (price return, excluding dividends). Past performance does not predict future results.
Are Milestone Pharmaceuticals and RenovoRx in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.